Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.

Autor: Vermeulen RFM; a Department of Gynecology , The Netherlands Cancer Institute , Amsterdam , the Netherlands., van Beurden M; a Department of Gynecology , The Netherlands Cancer Institute , Amsterdam , the Netherlands., Gaarenstroom KN; b Department of Gynecology , Leiden University Medical Center , Leiden , the Netherlands., Teunis T; c Plastic, Reconstructive and Hand Surgery , University Medical Center Utrecht , Utrecht , the Netherlands., Kieffer JM; d Division of Psychosocial Research and Epidemiology , The Netherlands Cancer Institute , Amsterdam , the Netherlands., Aaronson NK; d Division of Psychosocial Research and Epidemiology , The Netherlands Cancer Institute , Amsterdam , the Netherlands., Kenter GG; a Department of Gynecology , The Netherlands Cancer Institute , Amsterdam , the Netherlands., Korse CM; e Department of Laboratory Medicine , The Netherlands Cancer Institute , Amsterdam , the Netherlands.
Jazyk: angličtina
Zdroj: Climacteric : the journal of the International Menopause Society [Climacteric] 2018 Dec; Vol. 21 (6), pp. 574-580. Date of Electronic Publication: 2018 Oct 08.
DOI: 10.1080/13697137.2018.1512965
Abstrakt: Objectives: The aim of this study was to investigate whether serum anti-Müllerian hormone (AMH) predicts symptom burden after risk-reducing salpingo-oophorectomy (RRSO) in order to individualize counseling.
Methods: Patient-reported menopausal symptoms, sexual functioning, and psychological distress (depression and anxiety) were assessed 1 day before (T0) and 6 weeks (T1) and 7 months (T2) after RRSO. AMH was assessed before RRSO. Multivariable regression analysis was used to investigate the association between AMH and short-term and long-term change in symptom burden following RRSO.
Results: Ninety-one premenopausal women at high risk of ovarian cancer were included. Presurgical AMH was not related significantly to change in symptoms post RRSO. As a secondary outcome we found that regular menses before RRSO was associated specifically with long-term increase in hot flushes (sr = 0.40, p = 0.001; total R 2  = 0.171) and depression (sr = 0.29, p = 0.012; total R 2  = 0.132). Earlier receipt of chemotherapy was associated with long-term improvement in sexual functioning (sr = 0.24, p = 0.041; total R 2  = 0.348).
Conclusion: In this cohort, AMH was not a significant predictor of change in symptoms following RRSO. Regular menses prior to RRSO and earlier receipt of chemotherapy were significantly, but relatively weakly, associated with changes in outcomes 6 weeks and/or 7 months after RRSO.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje